Does penicillin remain the drug of choice for pneumococcal pneumonia in view of emerging in vitro resistance?

Clinical Infectious Diseases

Volumn 42, Issue 2, 2006, Pages 234-237

  Chiou, Christine C ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; MACROLIDE; PENICILLIN DERIVATIVE; PENICILLIN G; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; COMMUNICABLE DISEASE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CHOICE; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; HUMAN; IN VITRO STUDY; LOBAR PNEUMONIA; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; NONHUMAN; NOTE; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

HUMANS; PENICILLIN RESISTANCE; PENICILLINS; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 30144445116     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/499596     Document Type: Note

References (45)

1. Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60:759-76.
2. Hansman D, Glasgow H, Sturt J, Devitt L, Douglas R. Increase resistance to penicillin of pneumococci isolated from man. New Engl J Med 1971; 284:175-7.
3. Chiou CC, Liu YC, Huang TS, et al. Extremely high prevalence of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among children in Kaohsiung, Taiwan. J Clin Microbiol 1998; 36:1933-7.
4. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001; 45:1721-9.
5. Deeks S, Palacio R, Ruvinsky R, et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. Pediatrics 1999; 103:409-13.
6. Straus WL, Qazi SA, Kundi Z, Nomani NK, Schwartz B. Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxycillin for pneumonia among children in Pakistan: randomised controlled trial. Pakistan Co-trimoxazole Study Group. Lancet 1998; 352:270-4.
7. Friedland IR, Klugman KP. Antibiotic-resistant pneumococcal disease in South African children. Am J Dis Child 1992; 146:920-3.
8. Pallares R, Linares J, Vadillo M. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474-80.
9. Friedland IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J 1995; 14:885-90.
10. Plouffe JF, Breiman RF, Facklam RR. Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention. Franklin County Pneumonia Study Group. JAMA 1996; 275:194-8.
11. Carratalà J, Marron A, Fernández-Sevilla A, Liñares J, Gudiol F. Treatment of penicillin-resistant pneumococcal bacteremia in neutropenic patients with cancer. Clin Infect Dis 1997; 24:148-52.
12. Ewig S, Ruiz M, Torres A, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999; 159:1835-42.
13. Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999; 29:321-7.
14. Castillo EM, Rickman LS, Brodine SK, et al. Streptococcus pneumoniae: bacteremia in an era of penicillin resistance. Am J Infect Control 2000; 28:239-43.
15. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90:223-9.
16. Kalin M, Ortqvist A, Almela M, et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000; 182: 840-7.
17. Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30:520-8.
18. Watanabe H, Sato S, Kawakami K, et al. A comparative clinical study of pneumonia by penicillin-resistant and -sensitive Streptococcus pneumoniae in a community hospital. Respirology 2000; 5:59-64.
19. Roson B, Carratalà J, Tubau F, et al. Usefulness of beta-lactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone. Microb Drug Resist 2001; 7:85-96.
20. File TM Jr, Jacobs MR, Poole MD, Wynne B. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/ clavulanate. Clinical Study Groups 546, 547, 548, 549, 550, 551, 556, 557 and 592. Int J Antimicrob Agents 2002; 20:235-47.
21. Pallares R, Capdevila O, Linares J, et al. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am J Med 2002; 113:120-6.
22. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37:230-7.
23. Van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J. Breakthrough pneumococcal bacteremia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother 2003; 51:691-6.
24. Aspa J, Rajas O, Rodriguez de Castro F, et al. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Pneumococcal Pneumonia in Spain Study Group. Clin Infect Dis 2004; 38:787-98.
25. Falcò V, Almirante B, Jordano Q, et al. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains? J Antimicrob Chemother 2004; 54:481-8.
26. File TM Jr, Lode H, Kurz H, Kozak R, Xie H, Berkowitz E. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. 600 Study Group. Antimicrob Agents Chemother 2004; 48:3323-31.
27. Gonzalez BE, Martinez-Aguilar G, Mason EO Jr, Kaplan SL. Azithromycin compared with beta-lactam antibiotic treatment failures in pneumococcal infections of children. Pediatr Infect Dis J 2004; 23:399-405.
28. Roson B, Carratalà J, Fernádndez-Sabé N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004; 164:502-8.
29. Song JH, Jung SI, Ki HK, et al. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis 2004; 38:1570-8.
30. Peterson LR. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter? Clin Infect Dis 2006; 42:224-33 (in this issue).
31. Aspa J, Rajas O, Castro FR. Reply to Yu and Baddour. Clin Infect Dis 2004; 39:1087-8.
32. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromydn-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35:565-9.
33. Low DE. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin Infect Dis 2004; 38(Suppl 4): S357-62.
34. Musher DM, Bartlett JG, Doern GV. Fresh look at the definition of susceptibility of Streptococcus pneumoniae to beta-lactam antibiotics. Arch Intern Med 2001; 161:2538-44.
35. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial testing. 12th informational supplement. NCCLS document M100-S12. Wayne, PA: NCCLS, 2002.
36. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-12.
37. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22:89-96.
38. Andes D. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2001; 14:165-72.
39. Byran CS, Talwani R, Stinson MS. Penicillin dosing for pneumococcal pneumonia. Chest 1997; 112:1657-64.
40. Bishai W. The in-vivo and in-vitro paradox in pneumococcal respiratory tract infections. J Antimicrob Chemother 2002; 49:433-6.
41. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults. Clin Infect Dis 2003; 37: 1405-33.
42. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Grit Care Med 2004; 170:440-4.
43. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36:389-95.
44. Waterer GW, Somes GW, Wunderick RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837-42.
45. Weiss K, Low DE, Cortes L, et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004; 11:589-93.